




The relative strengths and weaknesses of Immune Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Immune Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 81% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	267
Cost of Goods Sold	0
Intangible Assets	3,607
Liabilities, Current	11,268
Liabilities, Non-Current	0
Other Assets	27,580
Other Compr. Net Income	0
Other Expenses	11
Other Liabilities	14,750
Other Net Income	3,251
Other Revenues	19
Property and Equipment	47
Research and Development	3,571
Selling, General and Administrative Expense	5,448

Output Variable	Value in 1000 USD
Assets	31,501
Liabilities	26,018
Expenses	9,030
Revenues	19
Stockholders Equity	5,483
Net Income	-5,760
Comprehensive Net Income	-5,760
BaseVar	34,910
ECR before LimitedLiability	22%
Economic Capital Ratio	162%